| Bioactivity | Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC). Anti-CD22-NMS249 is composed of a humanized anti-CD22 antibody Pinatuzumab (HY-P99230), a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor payload PNU-159682 (HY-16700). Anti-CD22-NMS249 can be used for research in non-Hodgkin lymphoma (NHL)[1]. |
| Invitro | Anti-CD22-NMS249 抑制 NHL 细胞系增殖，对 BJAB.Luc、Granta-519、SuDHL4.Luc 和 WSU-DLCL2 细胞的 IC50 值分别为 0.058 μg/mL、0.030 μg/mL、0.0221 μg/mL 和 0.010 μg/mL[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Anti-CD22-NMS249 相关抗体: |
| In Vivo | Anti-CD22-NMS249（0.5-2 mg/kg；静脉注射；单剂量）在四种异种移植模型中导致肿瘤停滞[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shang-Fan Yu, et al. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clin Cancer Res. 2015 Jul 15;21(14):3298-306. |